Safety and Efficacy of Switching From Either Unfractionated Heparin or Enoxaparin to Bivalirudin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Managed With an Invasive Strategy

Safety And Efficacy ◽

Invasive Strategy ◽

St Segment Elevation ◽

St Segment ◽

Faculty Opinions recommendation of Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108680.581591 ◽

2008 ◽

Author(s):

Michel Bertrand

Keyword(s):

Unfractionated Heparin ◽

Safety And Efficacy ◽

Invasive Strategy ◽

St Segment Elevation ◽

St Segment ◽

Faculty Opinions recommendation of Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108680.564774 ◽

2008 ◽

Author(s):

Harold Dauerman

Keyword(s):

Unfractionated Heparin ◽

Safety And Efficacy ◽

Invasive Strategy ◽

St Segment Elevation ◽

St Segment ◽

Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and AspirinA Randomized Controlled Trial

JAMA ◽

10.1001/jama.292.1.55 ◽

2004 ◽

Vol 292 (1) ◽

pp. 55 ◽

Cited By ~ 168

Author(s):

Michael A. Blazing

Keyword(s):

Randomized Controlled Trial ◽

Unfractionated Heparin ◽

Controlled Trial ◽

Safety And Efficacy ◽

St Segment Elevation ◽

Randomized Controlled ◽

St Segment ◽

Enoxaparin vs Unfractionated Heparin in High-Risk Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Managed With an Intended Early Invasive Strategy

JAMA ◽

10.1001/jama.292.1.45 ◽

2004 ◽

Vol 292 (1) ◽

Cited By ~ 223

Keyword(s):

High Risk ◽

Unfractionated Heparin ◽

Invasive Strategy ◽

St Segment Elevation ◽

High Risk Patients ◽

St Segment ◽

Risk Patients ◽

Coronary Syndromes ◽

Early Invasive Strategy

Safety and Efficacy of Enoxaparin vs Unfractionated Heparin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Who Receive Tirofiban and Aspirin: A Randomized Controlled Trial—Correction

JAMA ◽

10.1001/jama.292.10.1178 ◽

2004 ◽

Vol 292 (10) ◽

pp. 1178 ◽

Cited By ~ 1

Keyword(s):

Randomized Controlled Trial ◽

Unfractionated Heparin ◽

Controlled Trial ◽

Safety And Efficacy ◽

St Segment Elevation ◽

Randomized Controlled ◽

St Segment ◽

Safety and efficacy of enoxaparin vs. unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes. who receive tirofiban and aspirin

ACC Current Journal Review ◽

10.1016/j.accreview.2004.08.005 ◽

2004 ◽

Vol 13 (9) ◽

pp. 9

Author(s):

M.A. Blazing ◽

J.A. de Lemos ◽

H.D. White

Keyword(s):

Unfractionated Heparin ◽

Safety And Efficacy ◽

St Segment Elevation ◽

St Segment ◽

Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy

American Heart Journal ◽

10.1016/j.ahj.2012.10.001 ◽

2012 ◽

Vol 164 (6) ◽

pp. 817-824.e13 ◽

Cited By ~ 13

Author(s):

Philippe Gabriel Steg ◽

Shamir R. Mehta ◽

Charles V. Pollack ◽

Christoph Bode ◽

Christophe Gaudin ◽

...

Keyword(s):

Unfractionated Heparin ◽

Randomized Trial ◽

Double Blind ◽

Invasive Strategy ◽

St Segment Elevation ◽

St Segment ◽

Coronary Syndromes ◽

Early Invasive Strategy

Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide

Circulation ◽

10.1161/01.cir.0000050144.67910.13 ◽

2003 ◽

Vol 107 (2) ◽

pp. 238-244 ◽

Cited By ~ 144

Author(s):

Shaun G. Goodman ◽

David Fitchett ◽

Paul W. Armstrong ◽

Mary Tan ◽

Anatoly Langer

Keyword(s):

High Risk ◽

Unfractionated Heparin ◽

Safety And Efficacy ◽

St Segment Elevation ◽

High Risk Patients ◽

Randomized Evaluation ◽

St Segment ◽

Risk Patients ◽

Randomized evaluation of the safety and efficacy of enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide

ACC Current Journal Review ◽

10.1016/s1062-1458(03)00186-7 ◽

2003 ◽

Vol 12 (3) ◽

pp. 65

Author(s):

S.G. Goodman ◽

D. Fitchett ◽

P.W. Armstrong ◽

M. Tan ◽

A. Langer

Keyword(s):

High Risk ◽

Unfractionated Heparin ◽

Safety And Efficacy ◽

St Segment Elevation ◽

High Risk Patients ◽

Randomized Evaluation ◽

St Segment ◽

Risk Patients ◽

Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-Segment elevation acute coronary syndromes managed with an intended early invasive strategy—primary results of the SYNERGY randomized trial

ACC Current Journal Review ◽

10.1016/j.accreview.2004.08.036 ◽

2004 ◽

Vol 13 (9) ◽

pp. 28

Keyword(s):

High Risk ◽

Unfractionated Heparin ◽

Randomized Trial ◽

Invasive Strategy ◽

St Segment Elevation ◽

St Segment ◽

Risk Patients ◽

Coronary Syndromes ◽

Early Invasive Strategy